Health-car_老虎社区_美港股上老虎

2021-10-28

Health-care as in evergreen

AbbVie Takes Another Step Toward Its Post-Humira Future<blockquote>艾伯维(AbbVie)向修美乐(Humira)后的未来又迈出了一步</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":855519854,"tweetId":"855519854","gmtCreate":1635382655005,"gmtModify":1635382655242,"author":{"id":3578561972068295,"idStr":"3578561972068295","authorId":3578561972068295,"authorIdStr":"3578561972068295","name":"Eskay_Tew","avatar":"https://static.tigerbbs.com/c955d556458f3e647eb3cbf75c2f8f54","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":60,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Health-care as in evergreen&nbsp;</body></html>","htmlText":"<html><head></head><body>Health-care as in evergreen&nbsp;</body></html>","text":"Health-care as in evergreen","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/855519854","repostId":1139370497,"repostType":2,"repost":{"id":"1139370497","kind":"news","pubTimestamp":1635340322,"share":"https://www.laohu8.com/m/news/1139370497?lang=zh_CN&edition=full","pubTime":"2021-10-27 21:12","market":"us","language":"en","title":"AbbVie Takes Another Step Toward Its Post-Humira Future<blockquote>艾伯维(AbbVie)向修美乐(Humira)后的未来又迈出了一步</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1139370497","media":"Motley Fool","summary":"Since AbbVie(NYSE:ABBV) began trading in December 2012, it has left the S&P 500 in the dust. AbbVie ","content":"Since&nbsp;AbbVie(NYSE:ABBV)&nbsp;began trading in December 2012, it has left the&nbsp;S&amp;P 500&nbsp;in the dust. AbbVie has outperformed the S&amp;P 500 by nearly 60% in the past nine years. Most of the returns that AbbVie has generated for its shareholders have come from its top-selling drug in the world, Humira, which has grown sales from $9.3 billion in 2012 to just shy of $20 billion last year. But with the U.S. patents on Humira set to expire in 2023, AbbVie has been working diligently for many years to build a promising post-Humira future.<blockquote>自艾伯维（纽约证券交易所代码：ABBV）于2012年12月开始交易，已离开标普500在尘土中。艾伯维在过去九年中的表现优于标普500近60%。艾伯维为股东创造的大部分回报来自其全球最畅销药物修美乐(Humira)，该药物的销售额已从2012年的93亿美元增长到去年的近200亿美元。但随着Humira的美国专利将于2023年到期，艾伯维多年来一直在努力建设一个充满希望的后Humira未来。</blockquote> One of AbbVie's successors to Humira is the immunology drug known as Skyrizi. It recently received a recommendation from the European Union (E.U.) Committee for Medicinal Products for Human Use (CHMP) that it should be approved to treat adults with active psoriatic arthritis who have failed at least one other drug.<blockquote>艾伯维(AbbVie)Humira的继任者之一是名为Skyrizi的免疫学药物。它最近收到了欧盟（E.U.）人用药品委员会（CHMP）的建议，应批准其用于治疗至少一种其他药物治疗失败的活动性银屑病关节炎成人。</blockquote> Let's take a look at why this is a huge step for AbbVie in helping to move beyond Humira.<blockquote>让我们来看看为什么这是艾伯维在帮助超越修美乐方面迈出的一大步。</blockquote> Another treatment option for healthcare providers<blockquote>医疗服务提供者的另一种治疗选择</blockquote> Psoriatic arthritis (PsA) is a form of arthritis that leads to a condition known as psoriasis, which results in patches of itchy and scaly skin. PsA often causes symptoms of joint pain, swelling, and redness. Psoriasis is estimated to impact 2% to 3% of the global population. And approximately 30% of psoriasis patients eventually go on to develop psoriatic arthritis. Because 40% of patients with psoriatic arthritis report that their condition causes major problems in their daily life, it is crucial for them to seek treatment from their healthcare providers.<blockquote>银屑病关节炎（PsA）是一种关节炎，会导致银屑病，导致皮肤发痒和鳞状。PsA通常会导致关节疼痛、肿胀和发红的症状。据估计，银屑病影响2%至3%的全球人口。并且大约30%的银屑病患者最终继续发展为银屑病关节炎。因为40%的银屑病关节炎患者报告说，他们的病情给他们的日常生活带来了重大问题，所以向他们的医疗保健提供者寻求治疗对他们来说至关重要。</blockquote> Conventional synthetic disease-modifying anti-rheumatic drugs such as methotrexate are often the first-line treatment for patients with PsA. And although they work well for some patients, a recent study found that 71% of PsA patients fail their first-line therapy. This is where Skyrizi could potentially help countless patients.<blockquote>常规合成的缓解疾病的抗风湿药物如甲氨蝶呤通常是PsA患者的一线治疗药物。尽管它们对一些患者效果良好，但最近的一项研究发现，71%的PsA患者一线治疗失败。这就是Skyrizi可能帮助无数患者的地方。</blockquote> Based on results announced by AbbVie earlier this year, Skyrizi was demonstrated to be far superior to placebo in treating PsA. In fact, Skyrizi was far more likely to help PsA patients achieve at least a 90% skin clearance improvement as measured by the Psoriasis Area Severity Index (PASI90) at week 24 compared to placebo. And at least 52% of PsA patients receiving injections of Skyrizi across the two Phase 3 clinical trials achieved PASI90 at week 24 against just 10% of PsA patients who were injected with placebo. PsA patients receiving Skyrizi also reported notable improvements in their joint pain more frequently than those receiving placebo injections.<blockquote>根据艾伯维今年早些时候公布的结果，Skyrizi被证明在治疗PsA方面远远优于安慰剂。事实上，与安慰剂相比，Skyrizi更有可能帮助PsA患者在第24周通过银屑病区域严重程度指数（PASI90）测量实现至少90%的皮肤清除率改善。在两项3期临床试验中，至少有52%接受Skyrizi注射的PsA患者在第24周达到PASI90，而接受安慰剂注射的PsA患者只有10%达到PASI90。接受Skyrizi的PsA患者也比接受安慰剂注射的患者更频繁地报告关节疼痛明显改善。</blockquote> Based on this data and the news that the CHMP recommended that Skyrizi be approved, Skyrizi could be only months away from hitting the market in the E.U. The PsA indication for Skyrizi would be the second indication for the drug, joining its adult plaque psoriasis indication in the E.U.<blockquote>根据这些数据以及CHMP建议批准Skyrizi的消息，Skyrizi距离在欧盟上市可能只有几个月的时间了。Skyrizi的PsA适应症将是该药物的第二个适应症，加入其在欧盟的成人斑块型银屑病适应症。</blockquote> Psoriatic Arthritis would be a major indication for Skyrizi<blockquote>银屑病关节炎将是Skyrizi的主要适应症</blockquote> So, Skyrizi appears to be a great treatment option for PsA patients who haven't responded to first-line treatments. But what could a PsA indication in the European Union mean for AbbVie? Factoring in the E.U.'s population of 446 million, the 2% to 3% prevalence of psoriasis, and that 30% of psoriasis patients develop PsA, there are more than 2.7 million PsA patients living in the E.U.<blockquote>因此，对于一线治疗没有反应的PsA患者来说，Skyrizi似乎是一个很好的治疗选择。但欧盟的PsA适应症对艾伯维意味着什么呢？考虑到欧盟4.46亿人口、2%至3%的银屑病患病率以及30%的银屑病患者发展为PsA，有超过270万PsA患者生活在欧盟。</blockquote> And assuming that approximately 70% of PsA patients fail first-line therapy, this would indicate that there are at least 2 million PsA patients in the E.U. who have failed or will fail first-line therapy. Conservatively, one could assume that Skyrizi's potential PsA patient pool is 1 million. Since there are a variety of treatments available for PsA in the E.U. like Humira (and itsbiosimilars), I believe that Skyrizi will be able to capture 5% of the total market. This works out to around 50,000 patients.<blockquote>假设大约70%的PsA患者一线治疗失败，这将表明欧盟至少有200万PsA患者一线治疗失败或将失败。保守地说，人们可以假设Skyrizi的潜在PsA患者池为100万。由于欧盟有多种治疗PsA的方法。如Humira（及其生物仿制药），我相信Skyrizi将能够占据总市场的5%。这适用于大约50,000名患者。</blockquote> While Skyrizi's annual list price is $68,000 in the United States,&nbsp; drugs in large E.U. countries like Germany and France are anywhere from one-third to one-half of the U.S. list price. And this is before also considering insurance adjustments that lower the annual net price. Noting insurance adjustments, AbbVie will likely receive $20,000 in annual revenue per patient for Skyrizi, which equates to $1 billion in annual sales potential for a PsA indication.<blockquote>虽然Skyrizi在美国的年标价为68,000美元，但大型欧盟国家的药品。德国和法国等国家的价格是美国标价的三分之一到二分之一。这是在考虑降低年度净价的保险调整之前。考虑到保险调整，艾伯维可能会为Skyrizi获得每位患者20,000美元的年收入，这相当于PsA适应症的年销售潜力为10亿美元。</blockquote> Even for apharma stocksuch as AbbVie that analysts expect will generate $56.3 billion in revenue this year, a blockbuster indication like PsA for Skyrizi is a meaningful boost. Another indication for Skyrizi would add more fuel to the fast-growing drug, which has already recorded $1.2 billion in sales in the first half of this year.<blockquote>即使对于分析师预计今年将产生563亿美元收入的艾伯维(AbbVie)等制药股来说，Skyrizi的PsA等重磅指标也是一个有意义的提振。Skyrizi的另一个适应症将为这种快速增长的药物增添更多动力，该药物今年上半年的销售额已达到12亿美元。</blockquote> A high yielder that isn't too good to be true<blockquote>好得令人难以置信的高收益</blockquote> While AbbVie's&nbsp;4.8% dividend yield&nbsp;may come off as a yield trap at first glance, AbbVie is proof that you can't always judge a book by its cover. This is because the payout ratio is expected to be in the low 40% range this year.<blockquote>虽然艾伯维4.8%的股息收益率乍一看可能是一个收益率陷阱，但艾伯维证明了你不能总是以貌取人。这是因为今年的派息率预计将在40%的较低范围内。</blockquote> Since AbbVie was spun off from&nbsp;Abbott Laboratories(NYSE:ABT), AbbVie has raised its dividend each year. Because AbbVie inherited Abbott Laboratories' dividend increase streak and has raised its dividend each year since 2013, the stock is set to become a&nbsp;Dividend King&nbsp;with its next dividend increase, which is likely just days away. This will place it in the exclusive company of less than three dozen other stocks, which have raised their dividends at least 50 years straight. Analysts also expect that AbbVie will grow its adjusted earnings per share at 5% annually over the next five years, which should not only support the current dividend but allow future dividend growth.<blockquote>自从艾伯维从雅培实验室（纽约证券交易所股票代码：ABT），艾伯维每年都会提高股息。由于艾伯维(AbbVie)继承了雅培实验室(Abbott Laboratories)的股息增长势头，并且自2013年以来每年都提高股息，因此该股将在下一次股息增长中成为股息之王，而下一次股息增长可能只剩下几天了。这将使其成为不到三打其他股票中的独家公司，这些股票至少连续50年提高了股息。分析师还预计，艾伯维未来五年调整后每股收益将以每年5%的速度增长，这不仅应该支持当前的股息，还可以让未来的股息增长。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie Takes Another Step Toward Its Post-Humira Future<blockquote>艾伯维(AbbVie)向修美乐(Humira)后的未来又迈出了一步</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie Takes Another Step Toward Its Post-Humira Future<blockquote>艾伯维(AbbVie)向修美乐(Humira)后的未来又迈出了一步</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-10-27 21:12\n\n</h4>\n</header>\n<article>\nSince&nbsp;AbbVie(NYSE:ABBV)&nbsp;began trading in December 2012, it has left the&nbsp;S&amp;P 500&nbsp;in the dust. AbbVie has outperformed the S&amp;P 500 by nearly 60% in the past nine years. Most of the returns that AbbVie has generated for its shareholders have come from its top-selling drug in the world, Humira, which has grown sales from $9.3 billion in 2012 to just shy of $20 billion last year. But with the U.S. patents on Humira set to expire in 2023, AbbVie has been working diligently for many years to build a promising post-Humira future.<blockquote>自艾伯维（纽约证券交易所代码：ABBV）于2012年12月开始交易，已离开标普500在尘土中。艾伯维在过去九年中的表现优于标普500近60%。艾伯维为股东创造的大部分回报来自其全球最畅销药物修美乐(Humira)，该药物的销售额已从2012年的93亿美元增长到去年的近200亿美元。但随着Humira的美国专利将于2023年到期，艾伯维多年来一直在努力建设一个充满希望的后Humira未来。</blockquote> One of AbbVie's successors to Humira is the immunology drug known as Skyrizi. It recently received a recommendation from the European Union (E.U.) Committee for Medicinal Products for Human Use (CHMP) that it should be approved to treat adults with active psoriatic arthritis who have failed at least one other drug.<blockquote>艾伯维(AbbVie)Humira的继任者之一是名为Skyrizi的免疫学药物。它最近收到了欧盟（E.U.）人用药品委员会（CHMP）的建议，应批准其用于治疗至少一种其他药物治疗失败的活动性银屑病关节炎成人。</blockquote> Let's take a look at why this is a huge step for AbbVie in helping to move beyond Humira.<blockquote>让我们来看看为什么这是艾伯维在帮助超越修美乐方面迈出的一大步。</blockquote> Another treatment option for healthcare providers<blockquote>医疗服务提供者的另一种治疗选择</blockquote> Psoriatic arthritis (PsA) is a form of arthritis that leads to a condition known as psoriasis, which results in patches of itchy and scaly skin. PsA often causes symptoms of joint pain, swelling, and redness. Psoriasis is estimated to impact 2% to 3% of the global population. And approximately 30% of psoriasis patients eventually go on to develop psoriatic arthritis. Because 40% of patients with psoriatic arthritis report that their condition causes major problems in their daily life, it is crucial for them to seek treatment from their healthcare providers.<blockquote>银屑病关节炎（PsA）是一种关节炎，会导致银屑病，导致皮肤发痒和鳞状。PsA通常会导致关节疼痛、肿胀和发红的症状。据估计，银屑病影响2%至3%的全球人口。并且大约30%的银屑病患者最终继续发展为银屑病关节炎。因为40%的银屑病关节炎患者报告说，他们的病情给他们的日常生活带来了重大问题，所以向他们的医疗保健提供者寻求治疗对他们来说至关重要。</blockquote> Conventional synthetic disease-modifying anti-rheumatic drugs such as methotrexate are often the first-line treatment for patients with PsA. And although they work well for some patients, a recent study found that 71% of PsA patients fail their first-line therapy. This is where Skyrizi could potentially help countless patients.<blockquote>常规合成的缓解疾病的抗风湿药物如甲氨蝶呤通常是PsA患者的一线治疗药物。尽管它们对一些患者效果良好，但最近的一项研究发现，71%的PsA患者一线治疗失败。这就是Skyrizi可能帮助无数患者的地方。</blockquote> Based on results announced by AbbVie earlier this year, Skyrizi was demonstrated to be far superior to placebo in treating PsA. In fact, Skyrizi was far more likely to help PsA patients achieve at least a 90% skin clearance improvement as measured by the Psoriasis Area Severity Index (PASI90) at week 24 compared to placebo. And at least 52% of PsA patients receiving injections of Skyrizi across the two Phase 3 clinical trials achieved PASI90 at week 24 against just 10% of PsA patients who were injected with placebo. PsA patients receiving Skyrizi also reported notable improvements in their joint pain more frequently than those receiving placebo injections.<blockquote>根据艾伯维今年早些时候公布的结果，Skyrizi被证明在治疗PsA方面远远优于安慰剂。事实上，与安慰剂相比，Skyrizi更有可能帮助PsA患者在第24周通过银屑病区域严重程度指数（PASI90）测量实现至少90%的皮肤清除率改善。在两项3期临床试验中，至少有52%接受Skyrizi注射的PsA患者在第24周达到PASI90，而接受安慰剂注射的PsA患者只有10%达到PASI90。接受Skyrizi的PsA患者也比接受安慰剂注射的患者更频繁地报告关节疼痛明显改善。</blockquote> Based on this data and the news that the CHMP recommended that Skyrizi be approved, Skyrizi could be only months away from hitting the market in the E.U. The PsA indication for Skyrizi would be the second indication for the drug, joining its adult plaque psoriasis indication in the E.U.<blockquote>根据这些数据以及CHMP建议批准Skyrizi的消息，Skyrizi距离在欧盟上市可能只有几个月的时间了。Skyrizi的PsA适应症将是该药物的第二个适应症，加入其在欧盟的成人斑块型银屑病适应症。</blockquote> Psoriatic Arthritis would be a major indication for Skyrizi<blockquote>银屑病关节炎将是Skyrizi的主要适应症</blockquote> So, Skyrizi appears to be a great treatment option for PsA patients who haven't responded to first-line treatments. But what could a PsA indication in the European Union mean for AbbVie? Factoring in the E.U.'s population of 446 million, the 2% to 3% prevalence of psoriasis, and that 30% of psoriasis patients develop PsA, there are more than 2.7 million PsA patients living in the E.U.<blockquote>因此，对于一线治疗没有反应的PsA患者来说，Skyrizi似乎是一个很好的治疗选择。但欧盟的PsA适应症对艾伯维意味着什么呢？考虑到欧盟4.46亿人口、2%至3%的银屑病患病率以及30%的银屑病患者发展为PsA，有超过270万PsA患者生活在欧盟。</blockquote> And assuming that approximately 70% of PsA patients fail first-line therapy, this would indicate that there are at least 2 million PsA patients in the E.U. who have failed or will fail first-line therapy. Conservatively, one could assume that Skyrizi's potential PsA patient pool is 1 million. Since there are a variety of treatments available for PsA in the E.U. like Humira (and itsbiosimilars), I believe that Skyrizi will be able to capture 5% of the total market. This works out to around 50,000 patients.<blockquote>假设大约70%的PsA患者一线治疗失败，这将表明欧盟至少有200万PsA患者一线治疗失败或将失败。保守地说，人们可以假设Skyrizi的潜在PsA患者池为100万。由于欧盟有多种治疗PsA的方法。如Humira（及其生物仿制药），我相信Skyrizi将能够占据总市场的5%。这适用于大约50,000名患者。</blockquote> While Skyrizi's annual list price is $68,000 in the United States,&nbsp; drugs in large E.U. countries like Germany and France are anywhere from one-third to one-half of the U.S. list price. And this is before also considering insurance adjustments that lower the annual net price. Noting insurance adjustments, AbbVie will likely receive $20,000 in annual revenue per patient for Skyrizi, which equates to $1 billion in annual sales potential for a PsA indication.<blockquote>虽然Skyrizi在美国的年标价为68,000美元，但大型欧盟国家的药品。德国和法国等国家的价格是美国标价的三分之一到二分之一。这是在考虑降低年度净价的保险调整之前。考虑到保险调整，艾伯维可能会为Skyrizi获得每位患者20,000美元的年收入，这相当于PsA适应症的年销售潜力为10亿美元。</blockquote> Even for apharma stocksuch as AbbVie that analysts expect will generate $56.3 billion in revenue this year, a blockbuster indication like PsA for Skyrizi is a meaningful boost. Another indication for Skyrizi would add more fuel to the fast-growing drug, which has already recorded $1.2 billion in sales in the first half of this year.<blockquote>即使对于分析师预计今年将产生563亿美元收入的艾伯维(AbbVie)等制药股来说，Skyrizi的PsA等重磅指标也是一个有意义的提振。Skyrizi的另一个适应症将为这种快速增长的药物增添更多动力，该药物今年上半年的销售额已达到12亿美元。</blockquote> A high yielder that isn't too good to be true<blockquote>好得令人难以置信的高收益</blockquote> While AbbVie's&nbsp;4.8% dividend yield&nbsp;may come off as a yield trap at first glance, AbbVie is proof that you can't always judge a book by its cover. This is because the payout ratio is expected to be in the low 40% range this year.<blockquote>虽然艾伯维4.8%的股息收益率乍一看可能是一个收益率陷阱，但艾伯维证明了你不能总是以貌取人。这是因为今年的派息率预计将在40%的较低范围内。</blockquote> Since AbbVie was spun off from&nbsp;Abbott Laboratories(NYSE:ABT), AbbVie has raised its dividend each year. Because AbbVie inherited Abbott Laboratories' dividend increase streak and has raised its dividend each year since 2013, the stock is set to become a&nbsp;Dividend King&nbsp;with its next dividend increase, which is likely just days away. This will place it in the exclusive company of less than three dozen other stocks, which have raised their dividends at least 50 years straight. Analysts also expect that AbbVie will grow its adjusted earnings per share at 5% annually over the next five years, which should not only support the current dividend but allow future dividend growth.<blockquote>自从艾伯维从雅培实验室（纽约证券交易所股票代码：ABT），艾伯维每年都会提高股息。由于艾伯维(AbbVie)继承了雅培实验室(Abbott Laboratories)的股息增长势头，并且自2013年以来每年都提高股息，因此该股将在下一次股息增长中成为股息之王，而下一次股息增长可能只剩下几天了。这将使其成为不到三打其他股票中的独家公司，这些股票至少连续50年提高了股息。分析师还预计，艾伯维未来五年调整后每股收益将以每年5%的速度增长，这不仅应该支持当前的股息，还可以让未来的股息增长。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/10/27/abbvie-takes-big-step-toward-post-humira-future/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2021/10/27/abbvie-takes-big-step-toward-post-humira-future/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139370497","content_text":"Since AbbVie(NYSE:ABBV) began trading in December 2012, it has left the S&P 500 in the dust. AbbVie has outperformed the S&P 500 by nearly 60% in the past nine years. Most of the returns that AbbVie has generated for its shareholders have come from its top-selling drug in the world, Humira, which has grown sales from $9.3 billion in 2012 to just shy of $20 billion last year. But with the U.S. patents on Humira set to expire in 2023, AbbVie has been working diligently for many years to build a promising post-Humira future.\nOne of AbbVie's successors to Humira is the immunology drug known as Skyrizi. It recently received a recommendation from the European Union (E.U.) Committee for Medicinal Products for Human Use (CHMP) that it should be approved to treat adults with active psoriatic arthritis who have failed at least one other drug.\nLet's take a look at why this is a huge step for AbbVie in helping to move beyond Humira.\nAnother treatment option for healthcare providers\nPsoriatic arthritis (PsA) is a form of arthritis that leads to a condition known as psoriasis, which results in patches of itchy and scaly skin. PsA often causes symptoms of joint pain, swelling, and redness. Psoriasis is estimated to impact 2% to 3% of the global population. And approximately 30% of psoriasis patients eventually go on to develop psoriatic arthritis. Because 40% of patients with psoriatic arthritis report that their condition causes major problems in their daily life, it is crucial for them to seek treatment from their healthcare providers.\nConventional synthetic disease-modifying anti-rheumatic drugs such as methotrexate are often the first-line treatment for patients with PsA. And although they work well for some patients, a recent study found that 71% of PsA patients fail their first-line therapy. This is where Skyrizi could potentially help countless patients.\nBased on results announced by AbbVie earlier this year, Skyrizi was demonstrated to be far superior to placebo in treating PsA. In fact, Skyrizi was far more likely to help PsA patients achieve at least a 90% skin clearance improvement as measured by the Psoriasis Area Severity Index (PASI90) at week 24 compared to placebo. And at least 52% of PsA patients receiving injections of Skyrizi across the two Phase 3 clinical trials achieved PASI90 at week 24 against just 10% of PsA patients who were injected with placebo. PsA patients receiving Skyrizi also reported notable improvements in their joint pain more frequently than those receiving placebo injections.\nBased on this data and the news that the CHMP recommended that Skyrizi be approved, Skyrizi could be only months away from hitting the market in the E.U. The PsA indication for Skyrizi would be the second indication for the drug, joining its adult plaque psoriasis indication in the E.U.\nPsoriatic Arthritis would be a major indication for Skyrizi\nSo, Skyrizi appears to be a great treatment option for PsA patients who haven't responded to first-line treatments. But what could a PsA indication in the European Union mean for AbbVie? Factoring in the E.U.'s population of 446 million, the 2% to 3% prevalence of psoriasis, and that 30% of psoriasis patients develop PsA, there are more than 2.7 million PsA patients living in the E.U.\nAnd assuming that approximately 70% of PsA patients fail first-line therapy, this would indicate that there are at least 2 million PsA patients in the E.U. who have failed or will fail first-line therapy. Conservatively, one could assume that Skyrizi's potential PsA patient pool is 1 million. Since there are a variety of treatments available for PsA in the E.U. like Humira (and itsbiosimilars), I believe that Skyrizi will be able to capture 5% of the total market. This works out to around 50,000 patients.\nWhile Skyrizi's annual list price is $68,000 in the United States,  drugs in large E.U. countries like Germany and France are anywhere from one-third to one-half of the U.S. list price. And this is before also considering insurance adjustments that lower the annual net price. Noting insurance adjustments, AbbVie will likely receive $20,000 in annual revenue per patient for Skyrizi, which equates to $1 billion in annual sales potential for a PsA indication.\nEven for apharma stocksuch as AbbVie that analysts expect will generate $56.3 billion in revenue this year, a blockbuster indication like PsA for Skyrizi is a meaningful boost. Another indication for Skyrizi would add more fuel to the fast-growing drug, which has already recorded $1.2 billion in sales in the first half of this year.\nA high yielder that isn't too good to be true\nWhile AbbVie's 4.8% dividend yield may come off as a yield trap at first glance, AbbVie is proof that you can't always judge a book by its cover. This is because the payout ratio is expected to be in the low 40% range this year.\nSince AbbVie was spun off from Abbott Laboratories(NYSE:ABT), AbbVie has raised its dividend each year. Because AbbVie inherited Abbott Laboratories' dividend increase streak and has raised its dividend each year since 2013, the stock is set to become a Dividend King with its next dividend increase, which is likely just days away. This will place it in the exclusive company of less than three dozen other stocks, which have raised their dividends at least 50 years straight. Analysts also expect that AbbVie will grow its adjusted earnings per share at 5% annually over the next five years, which should not only support the current dividend but allow future dividend growth.","news_type":1,"symbols_score_info":{"ABBV":0.9}},"isVote":1,"tweetType":1,"viewCount":3309,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":24,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/855519854"}